AG
REGN icon

Ascent Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Ascent Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$291K Buy
377
+75
+25% +$57.4K 0.01% 630
2025
Q4 		$233K Sell
302
-279
-48% -$189K 0.01% 678
2025
Q3 		$327K Sell
581
-738
-56% -$417K 0.01% 578
2025
Q2 		$693K Sell
1,319
-5
-0.4% -$2.79K 0.03% 404
2025
Q1 		$840K Buy
1,324
+937
+242% +$644K 0.04% 356
2024
Q4 		$276K Sell
387
-83
-18% -$69.7K 0.02% 463
2024
Q3 		$494K Sell
470
-35
-7% -$39K 0.04% 376
2024
Q2 		$531K Hold
505
– – 0.04% 352
2024
Q1 		$486K Sell
505
-223
-31% -$212K 0.04% 362
2023
Q4 		$689K Sell
728
-37
-5% -$30.5K 0.07% 301
2023
Q3 		$612K Sell
765
-2,084
-73% -$1.64M 0.07% 290
2023
Q2 		$2.22M Buy
2,849
+1,034
+57% +$797K 0.24% 121
2023
Q1 		$1.49M Buy
1,815
+299
+20% +$226K 0.16% 178
2022
Q4 		$1.09M Buy
1,516
+117
+8% +$86.3K 0.13% 209
2022
Q3 		$1.05M Buy
1,399
+459
+49% +$289K 0.13% 203
2022
Q2 		$547K Buy
940
+334
+55% +$217K 0.07% 288
2022
Q1 		$423K Buy
606
+92
+18% +$58.2K 0.05% 347
2021
Q4 		$319K Buy
+514
New +$316K 0.04% 369

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ascent Group's REGN Position: Q1 2026 in Review

Ascent Group increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q1 2026, buying an estimated $57.4K and bringing the position to 377 shares worth $291K. The position accounts for 0.01% of the portfolio, ranked #630.

Ascent Group first reported a position in REGN in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.22M in Q2 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Ascent Group held 377 shares of Regeneron Pharmaceuticals worth $291K as of Q1 2026.
  • Ascent Group bought 75 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $57.4K.
  • Regeneron Pharmaceuticals made up 0.01% of Ascent Group's portfolio in Q1 2026, its #630 holding.
  • Ascent Group first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Ascent Group's Regeneron Pharmaceuticals position peaked at $2.22M in Q2 2023.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.